



(19)



(11) Publication number:

0 196 132 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication of patent specification: **12.08.92** (51) Int. Cl.⁵: **C07D 413/14, C07D 417/14, C07D 513/04, C07D 487/04, C07D 471/04, A61K 31/505, // (C07D513/04,277:00,239:00), (C07D513/04,279:00,239:00), (C07D487/04,239:00,209:00), (C07D487/04,239:00,223:00), (C07D471/04,239:00,221:00)**
(21) Application number: **86200400.9**
(22) Date of filing: **13.03.86**

The file contains technical information submitted after the application was filed and not included in this specification

(54) **1,2-Benzisoxazol-3-yl and 1,2-benzisothiazol-3-yl derivatives.**

(30) Priority: **27.03.85 US 717067**
(43) Date of publication of application: **01.10.86 Bulletin 86/40**
(45) Publication of the grant of the patent: **12.08.92 Bulletin 92/33**
(84) Designated Contracting States: **AT BE CH DE FR GB IT LI LU NL SE**
(56) References cited:
EP-A- 0 070 053 EP-A- 0 073 564
EP-A- 0 110 435 EP-A- 0 127 167
US-A- 4 342 870 US-A- 4 443 451

(73) Proprietor: **JANSSEN PHARMACEUTICA N.V.**
Turnhoutseweg 30
B-2340 Beerse(BE)
(72) Inventor: **Kennis, Ludo Edmond Josephine**
Guido Gezellesstraat 50
B-2300 Turnhout(BE)
Inventor: **Vandenberk, Jan**
Kempenlaan 15
B-2340 Beerse(BE)

BEST AVAILABLE COPY

EP 0 196 132 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).


Description

In U.S. Patent No. 4,352,811 and U.S. Patent No. 4,458,076 there are described 3-piperidinyl-1,2-benzisoxazoles and 3-piperidinyl-1,2-benzisothiazoles having antipsychotic and analgesic properties.

5 EP-A-0 110 435 discloses ((bis(aryl)methylene)-1-piperidinyl)alkyl-pyrimidinones useful in the treatment of psychosomatic disorders. EP-A-0 070 053 discloses bicyclic pyrimidin-5-one derivatives being psychotropic agents.

The compounds of the present invention differ from those prior art compounds by their substitution on the 1-position of the piperidine moiety.

10 The present invention is concerned with 1,2-benzazoles having the formula



and the pharmaceutically acceptable acid addition salts or possible stereochemically isomeric forms thereof, wherein


20 R is hydrogen or C₁-₆ alkyl;

R¹ and R² are each independently members selected from the group consisting of hydrogen, halo, hydroxy, C₁-₆ alkyloxy and C₁-₆ alkyl;

X is O or S;

Alk is C₁-₄ alkanediyl; and

25 Q is a radical of formula




35 wherein Y¹ and Y² are each independently O or S;

R³ is a member selected from the group consisting of hydrogen, halo, C₁-₆ alkyl, C₁-₆ alkyloxy, trifluoromethyl, nitro, cyano, hydroxy, (C₁-₁₀ alkylcarbonyl)oxy, amino, mono- and di(C₁-₆ alkyl)amino, (C₁-₁₀ alkylcarbonyl)amino, phenylmethoxy and azido;

R⁴ is hydrogen or halo; or

40 a radical of formula



wherein R⁵ is hydrogen or C₁-₆ alkyl;

50 Z is -S-, -CH₂- or -CR⁶ = CR⁷-, said R⁶ and R⁷ being each independently hydrogen or C₁-₆ alkyl; and

A is a bivalent radical -CH₂-CH₂-, -CH₂-CH₂-CH₂- or -CR⁸ = CR⁹-, said R⁸ and R⁹ being each independently hydrogen, halo, amino or C₁-₆ alkyl.

In the foregoing definitions the term halo is generic to fluoro, chloro, bromo and iodo; "C₁-₆ alkyl" is meant to include straight and branched saturated hydrocarbon radicals, having from 1 to 6 carbon atoms, such as, for example, methyl, ethyl, 1-methylethyl, 1,1-dimethylethyl, propyl, butyl, pentyl, hexyl; "C₁-₄ alkanediyl" is meant to include bivalent straight or branch chained alkanediyl radicals having from 1 to 4 carbon atoms, such as, for example, methylene, ethylene, propylene, butylene; and "C₁-₁₀ alkyl" is meant to include C₁-₆ alkyl radicals, as defined hereinabove, and the higher homologs thereof having from 7 to 10

carbon atoms, such as, for example, heptyl, nonyl.

Preferred compounds within the invention are those wherein Q is a radical of formula (a) wherein R³ is hydrogen, halo, C₁₋₆ alkyl, C₁₋₆ alkyloxy, trifluoromethyl, hydroxy, amino or azido and R⁴ is hydrogen; or Q is a radical of formula (b) wherein R⁵ is C₁₋₆ alkyl and A is a bivalent radical -CH₂-CH₂-, -CH₂-CH₂-CH₂- or -CR⁸=CR⁹- wherein R⁸ and R⁹ are each independently hydrogen or C₁₋₆ alkyl.


Particularly preferred compounds are those preferred compounds wherein R is hydrogen, R¹ is hydrogen or halo and R² is hydrogen, halo, hydroxy or C₁₋₆ alkyloxy.

More particularly preferred compounds are those particularly preferred compounds wherein Q is a radical of formula (a) wherein R³ is hydrogen, halo or methyl and Y¹ is O; or Q is a radical of formula (b) wherein -Z-A- is -S-CH₂-CH₂-, -S-(CH₂)₃-, -S-CR⁸=CR⁹- wherein R⁸ and R⁹ are each independently hydrogen or methyl, -CH=CH-CR⁸=CR⁹- wherein R⁸ and R⁹ are each independently hydrogen or methyl, or -CH₂-CH₂-CH₂-.

Especially preferred compounds are those more particularly preferred compounds wherein R¹ is hydrogen, and R² is hydrogen, halo, hydroxy or methoxy.

The most preferred compounds are selected from the group consisting of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one and 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one and the pharmaceutically acceptable acid addition salts thereof.



The compounds of formula (I) can generally be prepared by reacting an appropriate reactive ester of formula (II) with an appropriately substituted piperidine of formula (III). In the reactive ester (II) W represents a reactive ester residue such as, for example, halo, e.g., chloro, bromo or iodo, or a sulfonyloxy group, e.g. methylsulfonyloxy, (4-methylphenyl)sulfonyloxy.




The reaction of (II) with (III) can conveniently be conducted in an inert organic solvent such as, for example, an aromatic hydrocarbon, e.g., benzene, methylbenzene, dimethylbenzene; a lower alkanol, e.g., methanol, ethanol, 1-butanol and the like; a ketone, e.g., 2-propanone, 4-methyl-2-pentanone; an ether, e.g., 1,4-dioxane, 1,1'-oxybisethane, tetrahydrofuran; N,N-dimethylformamide (DMF); N,N-dimethylacetamide (DMA); nitrobenzene; 1-methyl-2-pyrrolidinone. The addition of an appropriate base such as, for example, an alkali or an earth alkaline metal carbonate, hydrogen carbonate, hydroxide, alkoxide or hydride, e.g., sodium carbonate, sodium hydrogen carbonate, potassium carbonate, sodium hydroxide, sodium methoxide, sodium hydride, or an organic base such as, for example, a tertiary amine, e.g., N,N-diethylethanamine, N-(1-methylethyl)-2-propanamine, 4-ethylmorpholine may be utilized to pick up the acid which is liberated during the course of the reaction. In some circumstances the addition of a iodide salt, preferably an alkali metal iodide, is appropriate. Somewhat elevated temperatures may enhance the rate of the reaction.

The compounds of formula (I) may also be prepared following art-known procedures for preparing compounds containing radicals of formula Q within their structure.


45 For example, the compounds of formula (I) wherein Q is a radical of formula (a), said compounds being represented by the formula (I-a), can be prepared by cyclizing an appropriate 2-amino-benzamide or 2-aminobenzenethioamide of formula (IV-a) with urea or thiourea.



The compounds of formula (I-a) can also be prepared by cyclizing an appropriate intermediate of formula (IV-b) with an amine of formula (V)




or by cyclizing an isocyanate or isothiocyanate of formula (IV-c) with a primary amine of formula (V).



The said cyclization-reactions are conveniently conducted by stirring and, if desired, heating the reactants together, optionally in a suitable reaction-inert solvent having a relatively high boiling point such as aliphatic and aromatic hydrocarbons, e.g. petroleum ether, dimethylbenzene.

In the foregoing reaction schemes R¹⁰ and R^{10-a} each independently represent an appropriate leaving group such as, for example, C₁₋₆ alkoxy, amino, and mono- and di(C₁₋₆ alkyl)amino.


The compounds of formula (I) wherein Q is a radical of formula (b), said compounds being represented by the formula (I-b), can be prepared following art-known cyclizing procedures for preparing pyrimidin-4-ones such as, for example, by reacting an amine of formula (VI) with a cyclizing agent of formula (VII) or by cyclizing a reagent of formula (VIII) with an amine of formula (IX).




The said cyclization reactions may generally be carried out by stirring the reactants together, if desired, in the presence of a suitable reaction-inert solvent such as, for example, an aliphatic-, alicyclic- or aromatic hydrocarbon, e.g., hexane, cyclohexane, benzene; pyridine; N,N-dimethylformamide. Elevated temperatures may be appropriate to enhance the reaction-rate. In some cases it may be preferable to carry out the reaction at the reflux temperature of the reaction mixture.

In the foregoing reaction schemes L and L¹ each independently represent an appropriate leaving group such as, for example, (C₁₋₆ alkyl)oxy, hydroxy, halo, amino, mono- and di(C₁₋₆ alkyl)amino.

Following the same cyclization procedure the compounds of formula (I-b) can also be prepared by cyclizing an intermediate of formula (IX) with a reagent of formula (X).



50 The compounds of formula (I-b) wherein Z is S, said compounds being represented by the formula (I-b-1), can also be prepared by cyclizing a 2-mercaptopyrimidinone of formula (XI) with a reagent of formula (XII).




metal or earth alkaline metal thereof and subsequently converting the said diazonium group into an azide group with sodium azide or any other suitable alkali metal or earth alkaline metal azide.

The compounds of formula (I) have basic properties and, consequently, they may be converted to their therapeutically active non-toxic acid addition salt forms by treatment with appropriate acids, such as, for example, inorganic acids, such as hydrohalic acid, e.g. hydrochloric, hydrobromic and the like, and sulfuric acid, nitric acid, phosphoric acid and the like; or organic acids, such as, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, ethanedioic, propanedioic, butanedioic, (Z)-2-butenedioic, (E)-2-butenedioic, 2-hydroxybutanedioic, 2,3-dihydroxybutanedioic, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic. Conversely the salt form can be converted by treatment with alkali into the free base form.

A number of intermediates and starting materials in the foregoing preparations are known compounds which may be prepared according to art-known methodologies of preparing said or similar compounds. For example, the intermediates of formula (II) and their preparations are described in U.S. Patent Nos. 4,335,127; 4,342,870; 4,443,451; and 4,485,107. Other intermediates may be prepared according to art-known methodologies of preparing similar compounds and for some of them preparative methods are presented hereinafter.

The intermediates of formula (III) may generally be derived from a benzoylpiperidine of formula


20



25

wherein halo is preferably fluoro, following art-known procedures, e.g. by reacting the benzoylpiperidine (XIV) with hydroxylamine and cyclizing the thus obtained oxime


30



35

40 following art-known procedures, thus obtaining the intermediate of formula (III) wherein X is O, said intermediates being represented by the formula


45



50

The intermediates of formula (III) wherein X is S, said intermediates being represented by the formula

55



may be prepared following a procedure analogous to the procedure described in U.S. Patent No. 4,458,076.

The compounds of formula (I) and the pharmaceutical acceptable acid addition salts thereof are potent antagonists of a series of neurotransmitters and as a result they have useful pharmacological properties. For example, the compounds of formula (I) and their pharmaceutically acceptable acid addition salts possess

5 strong psychotic activity and antiserotonine activity.

Due to their pharmacological activities the compounds of formula (I) and their pharmaceutically acceptable acid addition salts can be used in the treatment of psychotic diseases and in the treatment of a variety of complaints in which serotonin release is of predominant importance such as, for example, in the blocking of serotonin-induced contractions of bronchial tissues and of blood vessels, arteries as well as

10 veins. The subject compounds have also useful properties as sedating-, anxiolytic-, anti-aggressive-, anti-

stress-, muscular protectant- and cardiovascular protectant agents and, consequently, they are useful to

protect warm-blooded animals, for example, in stress situations, e.g., during transport periods. Additionally,

the subject compounds are useful as protectors of endotoxine shocks and as antidiarrhoeals.

In view of their useful pharmacological properties, the subject compounds may be formulated into

15 various pharmaceutical forms for administration purposes. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, in base or acid-addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration

20 orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions: or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents in the

25 case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for

example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid

30 carriers, suspending agents may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wettable agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not introduce a significant deleterious effect on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be admin-

35 istered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. Acid addition salts of (I)

due to their increased water solubility over the corresponding base form, are obviously more suitable in the

preparation of aqueous compositions.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage

unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification

40 and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a

predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in associa-

tion with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including

scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions,

teaspoonfuls, tablespoon-fuls, and segregated multiples thereof.

45 In the following examples, unless otherwise stated, all parts are by weight and all temperatures are in

the centigrade scale.

EXPERIMENTAL PART

50 A) Preparation of the intermediates

Example 1

To a stirred mixture of 65 parts of 1,3-difluorobenzene, 130 parts of aluminium chloride and 195 parts of

55 dichloromethane was added dropwise a solution of 95 parts of 1-acetyl-4-piperidine-carbonyl chloride in 65

parts of dichloromethane while cooling. Upon completion, stirring was continued for 3 hours at room

temperature. The reaction mixture was poured into a mixture of crushed ice and hydrochloric acid. The

product was extracted with dichloromethane. The organic layer was dried, filtered and evaporated, yielding

48 parts (36%) of 1-acetyl-4-(2,4-difluorobenzoyl)piperidine as a residue (intermediate 1).

A mixture of 48 parts of 1-acetyl-4-(2,4-difluorobenzoyl)piperidine and 180 parts of a hydrochloric acid solution 6N was stirred and refluxed for 5 hours. The reaction mixture was evaporated and the residue was stirred in 2-propanol. The product was filtered off and dried, yielding 39 parts (83%) of (2,4-difluorophenyl)-(4-piperidinyl)methanone hydrochloride (intermediate 2).

A mixture of 12 parts of (2,4-difluorophenyl)(4-piperidinyl)methanone hydrochloride, 12 parts of hydroxylamine hydrochloride and 120 parts of ethanol was stirred at room temperature and 10.5 parts of N,N-diethylethanamine were added. The whole was stirred and refluxed for 3 hours. After cooling, the precipitated product was filtered off and dried, yielding 11 parts (100%) of (2,4-difluorophenyl)(4-piperidinyl)methanone, oxime (intermediate 3).

A mixture of 11 parts of (2,4-difluorophenyl)(4-piperidinyl)methanone, oxime, 25 parts of potassium hydroxide and 25 parts of water was stirred and refluxed for 2 hours. The reaction mixture was cooled and extracted with methylbenzene. The extract was dried, filtered and evaporated. The residue was crystallized from petroleumether, yielding 6.8 parts of 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole (intermediate 4).

15

Example 2

A mixture of 50 parts of 2-thiazolamine, 76 parts of 3-acetyl-4,5-dihydro-2(3H)-furanone, 1.2 parts of concentrate hydrochloric acid and 270 parts of methylbenzene was stirred and refluxed for 2 hours using a water-separator. The reaction mixture was cooled and 340 parts of phosphoryl chloride were added at a temperature between 20 and 30 °C. The whole was heated slowly to 100-110 °C and stirring was continued for 2 hours at this temperature. The reaction mixture was evaporated and the residue was poured into a mixture of crushed ice and ammonium hydroxide. The product was extracted with trichloromethane. The extract was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from a mixture of 2-propanol and 1,1'-oxybisethane, yielding 36 parts of 6-(2-chloroethyl)-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one (intermediate 5).

30

Example 3

A mixture of 30 parts of 4-hydroxy-2-mercaptop-6-methyl-5-pyrimidineethanol, 25 parts of potassium carbonate, 270 parts of N,N-dimethylacetamide and 75 parts of water was stirred at room temperature and 36 parts of 1,3-dibromopropane were added at once: temperature rose to 50 °C. The whole was stirred overnight at room temperature. The reaction mixture was evaporated and water was added to the residue. The solid product was washed with water and dried in vacuo at 100 °C, yielding 21 parts (58%) of 3,4-dihydro-7-(2-hydroxyethyl)-8-methyl-2H,6H-pyrimido-[2,1-b][1,3]thiazin-6-one; mp. 155 °C (intermediate 6).

Following the same procedure and using equivalent amounts of the appropriate starting materials, there was also prepared:

40

2,3-dihydro-6-(2-hydroxyethyl)-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one; mp. 148.7 °C (intermediate 7).

Example 4

A mixture of 20 parts of 3,4-dihydro-7-(2-hydroxyethyl)-8-methyl-2H,6H-pyrimido[2,1-b][1,3]thiazin-6-one, 50 parts of acetic acid and 180 parts of a hydrobromic acid solution 67% in acetic acid was stirred and heated to reflux. Stirring was continued overnight at reflux temperature. The reaction mixture was evaporated and the solid residue was triturated in 2-propanone. The product was filtered off and dried, yielding 24 parts (100%) of 7-(2-bromoethyl)-3,4-dihydro-8-methyl-2H,6H-pyrimido[2,1-b][1,3]thiazin-6-one; monohydrobromide; mp. 215 °C (intermediate 8).

50

Following the same procedure and using equivalent amounts of the appropriate starting materials, there was also prepared:

6-(2-bromoethyl)-2,3-dihydro-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one monohydrochloride; mp. 237.2 °C (intermediate 9).

55

B) Preparation of the final compounds

Example 5

A mixture of 5.3 parts of 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one monohydrochloride, 4.4 parts of 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole, 8 parts of sodium carbonate, 0.1 parts of potassium iodide and 90 parts of N,N-dimethylformamide was stirred overnight at 85~90°C. After cooling, the reaction mixture was poured into water. The product was filtered off and crystallized from a mixture of N,N-dimethylformamide and 2-propanol. The product was filtered off and dried, yielding 3.8 parts (46%) of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 170.0°C (compound 1).

Following the same procedure and using equivalent amounts of the appropriate starting materials, there were also prepared:

10 6-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one; mp. 165.1°C (compound 2);
 3-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 177.9°C (compound 3);
 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,7-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 186.9°C (compound 4);
 3-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 183.1°C (compound 5);
 3-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazolinedione monohydrochloride; mp. >300°C (dec.) (compound 6);
 20 3-[2-[4-(1,2-benzisothiazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 145.7°C (compound 7);
 3-[2-[4-(6-hydroxy-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 213.1°C (compound 8).

In the similar manner are prepared

25 3-[2-[4-(5-methoxy-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (compound 9);
 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (compound 10).

30 Example 6

A mixture of 3.3 parts of 3-(2-chloroethyl)-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one, 3.3 parts of 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole, 8 parts of sodium carbonate, 1 part of potassium iodide and 120 parts of 4-methyl-2-pentanone was stirred and refluxed for 3 hours. The reaction mixture was cooled, water was added and the layers were separated. The organic phase was dried, filtered and evaporated. The residue was purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. The residue was crystallized from 4-methyl-2-pentanone, yielding 1.2 parts (19%) of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 170.4°C (compound 11).

Example 7

A mixture of 6.75 parts of 3-(2-chloroethyl)-2,4(1H,3H)-quinazolinedione, 6.6 parts of 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole, 10 parts of sodium hydrogen carbonate, 0.1 parts of potassium iodide and 90 parts of N,N-dimethylformamide was stirred and heated overnight at 100~110°C. After cooling, the reaction mixture was poured into water. After stirring, the product was filtered off and crystallized from N,N-dimethylformamide, yielding 4.8 parts (39%) of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,4(1H,3H)-quinazolinedione; mp. 253.4°C (compound 12).

50 Example 8

A mixture of 7.4 parts of 6-(2-bromoethyl)-3,7-dimethyl-5H-thiazolo[3,2-a]pyrimidin-5-one monohydrobromide, 4.4 parts of 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole, 10 parts of sodium carbonate and 90 parts of N,N-dimethylformamide was stirred overnight at 80~85°C. After cooling, the reaction mixture was poured into water. The product was filtered off and purified by column chromatography over silica gel using a mixture of trichloromethane and methanol (95:5 by volume) as eluent. The pure fractions were collected and the eluent was evaporated. 2-Propanol was added to the residue. The product was filtered off

and dried, yielding 5.3 parts (62%) of 6-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-3,7-dimethyl-5H-thiazolo[3,2-a]pyrimidin-5-one; mp. 231.0 °C (compound 13).

In a similar manner there were also prepared:

6-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,3-dihydro-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one; mp. 135.0 °C (compound 14);
 7-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-3,4-dihydro-8-methyl-2H,6H-pyrimido[2,1-b][1,3]-thiazin-6-one; mp. 169.3 °C (compound 15);
 6-[2-[4-(1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,3-dihydro-7-methyl-5H-thiazolo[3,2-a]pyrimidin-5-one; mp. 154.5 °C (compound 16);
 3-[2-[4-(6-fluoro-1,2-benzisothiazol-3-yl)-1-piperidinyl]ethyl]-6,7,8, 9-tetrahydro-2-methyl-4H-pyrido[1,2-a]-pyrimidin-4-one (compound 17);
 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,3-dihydro-2-thioxo-4(1H)-quinazolinone (compound 18).

C) Pharmacological examples

The activity of the subject compounds as psychotic agents is evidenced by the experimental data obtained in at least one of two different test procedures, viz., the combined apomorphine-, tryptamine- and norepinephrine tests in rats and the apomorphine test in dogs. The tests are carried out following the procedures described hereafter and the experimental data are summarized in table 1.

Example 9

25 The combined apomorphine (APO)-, tryptamine (TRY)- and norepinephrine (NOR) test in rats.

The experimental animals used in this test were adult male Wistar rats (weight 240 ± 10g). After an overnight fast, the animals were treated subcutaneously (1ml/100g) with an aqueous solution of the compound under investigation (time = zero) and put in isolated observation cages. Thirty minutes thereafter (time = 30 minutes) 1.25 mg/kg of apomorphine hydrochloride (APO) was injected intravenously and the rats were observed over a 1 hour period for the presence or absence of the following apomorphine-induced phenomena: agitation and stereotypic chewing. At the end of this 1 hour period (time = 90 minutes) the same animals were injected intravenously with 40 mg/kg of tryptamine (TRY) and the presence of the typical tryptamine-induced bilateral tonic seizures was noted. Two hours after pretreatment (time = 120 minutes) finally, the same animals were challenged with 1.25 mg/kg intravenously of norepinephrine (NOR) and possible mortality was looked for up to 60 minutes later.

The table 1 gives the ED₅₀-values of a number of the compounds under consideration. As used herein, the ED₅₀-value represents the dose which protects 50% of the animals from apomorphine-, tryptamine- or norepinephrine-induced phenomena.

40 The apomorphine test in dogs (APO-dog).

The method used is described by P.A.J. Janssen and C.J.E. Niemegeers in Arzneim.-Forsch. (Drug Res.), 9, 765-767 (1959). The compounds listed in table 1 were administered subcutaneously to beagle dogs at different doses and the animals were challenged 1 hour thereafter with a standard dose of 0.31 mg/kg (subcutaneous) of apomorphine.

The table 1 gives the ED₅₀-values of a number of the compounds under consideration. As used herein, the ED₅₀ value represents the dose which protects 50% of the animals from emesis.

The compounds listed in table 1 are not given for the purpose of limiting the invention thereto but only to exemplify the useful pharmacological activities of all the compounds within the scope of formula (I).

Table I

Compound No.	ED ₅₀ (APO)-rat in mg/kg s.c.	ED ₅₀ (TRY)-rat in mg/kg s.c.	ED ₅₀ (NOR)-rat in mg/kg s.c.	ED ₅₀ (APO)-dog in mg/kg s.c.	duration
1	0.08	0.08	0.16	1h. 2h. 4h. 8h. 16h.	0.008 0.005 0.015 0.018 0.02
2	0.02	0.005	0.31	1h. 4h. 16h.	0.004 0.008 0.16
11	0.02	0.01	0.16	1h. 4h. 16h.	0.015 0.03 0.16
13	0.02	0.02	0.08	1h. 4h. 1h.	0.015 0.06 0.004
14	0.02	0.005	0.31	4h. 1h.	0.004 0.015
15	0.08	0.01	0.31	1h. 4h.	0.015 0.06

D) Composition Examples

The following formulations exemplify typical pharmaceutical compositions in dosage unit form suitable for systemic administration to animal and human subjects in accordance with the instant invention.

"Active ingredient" (A.I.) as used throughout these examples relates to a compound of formula (I) or a pharmaceutically acceptable acid addition salt thereof.

Example 10 : ORAL DROPS

500 Grams of the A.I. was dissolved in 0.5 liters of 2-hydroxypropanoic acid and 1.5 liters of the polyethylene glycol at 60~80°C. After cooling to 30~40°C there were added 35 liters of polyethylene glycol and the mixture was stirred well. Then there was added a solution of 1750 grams of sodium saccharin in 2.5 liters of purified water and while stirring there were added 2.5 liters of cocoa flavor and

polyethylene glycol q.s. to a volume of 50 liters, providing an oral drop solution comprising 10 milligrams of the A.I. per milliliter. The resulting solution was filled into suitable containers.

Example 11 : ORAL SOLUTION

5 9 Grams of methyl 4-hydroxybenzoate and 1 gram of propyl 4-hydroxybenzoate were dissolved in 4 liters of boiling purified water. In 3 liters of this solution were dissolved first 10 grams of 2,3-dihydroxybutanedioic acid and thereafter 20 grams of the A.I. The latter solution was combined with the remaining part of the former solution and 12 liters 1,2,3-propanetriol and 3 liters of sorbitol 70% solution were added thereto. 10 40 Grams of sodium saccharin were dissolved in 0.5 liters of water and 2 milliliters of raspberry and 2 milliliters of gooseberry essence were added. The latter solution was combined with the former, water was added q.s. to a volume of 20 liters providing an oral solution comprising 20 milligrams of the active ingredient per teaspoonful (5 milliliters). The resulting solution was filled in suitable containers.

15 Example 12 : CAPSULES

20 20 Grams of the A.I., 6 grams sodium lauryl sulfate, 56 grams starch, 56 grams lactose, 0.8 grams colloidal silicon dioxide, and 1.2 grams magnesium stearate were vigorously stirred together. The resulting mixture was subsequently filled into 1000 suitable hardened gelating capsules, comprising each 20 milligrams of the active ingredient.

Example 13 : FILM-COATED TABLETS

Preparation of tablet core

25 A mixture of 100 grams of the A.I., 570 grams lactose and 200 grams starch was mixed well and thereafter humidified with a solution of 5 grams sodium dodecyl sulfate and 10 grams polyvinylpyrrolidone (Kollidon-K 90®) in about 200 milliliters of water. The wet powder mixture was sieved, dried and sieved again. Then there was added 100 grams microcrystalline cellulose (Avicel®) and 15 grams hydrogenated 30 vegetable oil (Sterotex ®). The whole was mixed well and compressed into tablets, giving 10.000 tablets, each containing 10 milligrams of the active ingredient.

Coating

35 To a solution of 10 grams methyl cellulose (Methocel 60 HG®) in 75 milliliters of denatured ethanol there was added a solution of 5 grams of ethyl cellulose (Ethocel 22 cps ®) in 150 milliliters of dichloromethane. Then there were added 75 milliliters of dichloromethane and 2.5 milliliters 1,2,3-propanetriol. 10 Grams of polyethylene glycol was molten and dissolved in 75 milliliters of dichloromethane. The latter solution was added to the former and then there were added 2.5 grams of magnesium 40 octadecanoate, 5 grams of polyvinylpyrrolidone and 30 milliliters of concentrated colour suspension (Opaspray K-1-2109®) and the whole was homogenated.

The tablet cores were coated with the thus obtained mixture in a coating apparatus.

Example 14 : INJECTABLE SOLUTION

45 1.8 Grams methyl 4-hydroxybenzoate and 0.2 grams propyl 4-hydroxybenzoate were dissolved in about 0.5 liters of boiling water for injection. After cooling to about 50 °C there were added while stirring 4 grams lactic acid, 0.05 grams propylene glycol and 4 grams of the A.I.. The solution was cooled to room temperature and supplemented with water for injection q.s. ad 1 liter volume, giving a solution of 4 milligrams A.I. per milliliters. The solution was sterilized by filtration (U.S.P. XVII p. 811) and filled in sterile 50 containers.


Example 15 : SUPPOSITORIES

55 3 Grams A.I. was dissolved in a solution of 3 grams 2,3-dihydroxybutanedioic acid in 25 milliliters polyethylene glycol 400. 12 Grams surfactant (SPAN®) and triglycerides (Witepsol 555 ®) q.s. ad 300 grams were molten together. The latter mixture was mixed well with the former solution. The thus obtained mixture was poured into moulds at a temperature of 37-38 °C to form 100 suppositories each containing 30

milligrams of the active ingredient.

Claims

5 1. A chemical compound having the formula



15 or a pharmaceutically acceptable acid addition salt thereof,

wherein


R is hydrogen or C₁-₆ alkyl;

R¹ and R² are each independently members selected from the group consisting of hydrogen, halo, hydroxy, C₁-₆ alkyloxy and C₁-₆ alkyl;

20 X is O or S;

Alk is C₁-₄ alkanediyl; and


Q is a radical of formula



30 wherein Y¹ and Y² are each independently O or S;

R³ is a member selected from the group consisting of hydrogen, halo, C₁-₆ alkyl, C₁-₆ alkyloxy, trifluoromethyl, nitro, cyano, hydroxy, (C₁-₁₀ alkylcarbonyloxy, amino, mono- and di(C₁-₆ alkyl)amino, (C₁-₁₀ alkylcarbonyl)amino, phenylmethoxy and azido;

35 R⁴ is hydrogen or halo; or
a radical of formula



45 wherein R⁵ is hydrogen or C₁-₆ alkyl;

Z is -S-, -CH₂- or -CR⁶ = CR⁷-; said R⁶ and R⁷ being each independently hydrogen or C₁-₆ alkyl;
and

50 A is a bivalent radical -CH₂-CH₂-, -CH₂-CH₂-CH₂- or -CR⁸ = CR⁹-, said R⁸ and R⁹ being each independently hydrogen, halo, amino or C₁-₆ alkyl.

2. A chemical compound according to claim 1, wherein Q is a radical of formula (a) wherein R³ is hydrogen, halo, C₁-₆ alkyl, C₁-₆ alkyloxy, trifluoromethyl, hydroxy, amino or azido and R⁴ is hydrogen; or Q is a radical of formula (b) wherein R⁵ is C₁-₆ alkyl and A is a bivalent radical -CH₂-CH₂-, -CH₂-CH₂- or -CR⁸ = CR⁹- wherein R⁸ and R⁹ are each independently hydrogen or C₁-₆ alkyl.

3. A chemical compound according to claim 2, wherein R is hydrogen, R¹ is hydrogen or halo and R² is hydrogen, halo, hydroxy or C₁-₆ alkyloxy.

4. A chemical compound according to claim 3, wherein Q is a radical of formula (a) wherein R³ is hydrogen, halo or methyl and Y¹ is O; or Q is a radical of formula (b) wherein -Z-A- is -S-CH₂-CH₂-, -S-(CH₂)₃-, -S-CR⁸=CR⁹- wherein R⁸ and R⁹ are each independently hydrogen or methyl, -CH=CH-CR⁸=CR⁹-wherein R⁸ and R⁹ are each independently hydrogen or methyl, or -CH₂-CH₂-CH₂-CH₂-.

5. A chemical compound according to claim 4, wherein R¹ is hydrogen, and R² is hydrogen, halo, hydroxy or methoxy.

6. A chemical compound according to claim 1 wherein the compound is 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one or 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one.

7. A pharmaceutical composition comprising a suitable pharmaceutical carrier and as an active ingredient a therapeutically active amount of a compound as claimed in any one of claims 1 to 6.

8. A pharmaceutical composition for treating psychotic diseases comprising a suitable pharmaceutical carrier and as an active ingredient an amount effective in treating psychotic diseases of a compound as claimed in any one of claims 1 to 6.

9. A method of preparing a pharmaceutical composition characterized in that a therapeutically effective amount of a compound as claimed in any one of claims 1 to 6 is intimately mixed with suitable pharmaceutical carriers.

10. A compound as claimed in any one of claims 1 to 6 for use as a medicine.


11. A compound as claimed in any one of claims 1 to 6 for use as a medicine for treating psychotic diseases.

12. A process for preparing a chemical compound as claimed in any of claims 1 to 6, characterized by


30 a) reacting a derivative ester of formula




wherein W represents a reactive ester residue with a piperidine of formula




in a reaction-inert solvent;
b) cyclizing an intermediate of formula




55 with urea or thiourea, optionally in a reaction-inert solvent, thus preparing a compound of formula




10 c) cyclizing an intermediate of formula



20 wherein R¹⁰ and R^{10-a} each independently represent a leaving group such as, C₁₋₆ alkyloxy, amino and mono- and di(C₁₋₆ alkyl)amino, with an amine of formula




30 optionally in a reaction-inert solvent, thus preparing a compound of formula (I-a);
d) cyclizing an isocyanate or isothiocyanate of formula




40 with an amine of formula (V), optionally in a reaction-inert solvent, thus preparing a compound of formula (I-a);

e) reacting an amine of formula



50 with a α -carbonylcarboxylic acid derivative of formula


5



10


wherein L represents a leaving group such as, C₁₋₆ alkyloxy, hydroxy, halo, amino, mono- and di-(C₁₋₆ alkyl)amino, thus preparing a compound of formula

15



20


25



with an β -aminocarboxylic acid derivative of formula

30

35



40

said L and L¹ each independently representing a leaving group such as, C₁₋₆ alkyloxy, hydroxy, halo, amino, mono- and di(C₁₋₆ alkyl)amino, thus preparing a compound of formula (I-b);

45

g) cyclizing a nitrile of formula

45




50

with an β -aminocarboxylic acid derivative of formula (IX) said L representing a leaving group such as, C₁₋₆ alkyloxy, hydroxy, halo, amino, mono- and di(C₁₋₆ alkyl)amino, thus preparing a compound of formula (I-b);

h) cyclizing a 2-mercaptopurimidinone of formula

55

5



10


15



25

30

35




or

i) cyclizing a 2-mercaptopurine of formula (XI) with a reagent of formula




40

thus preparing a compound of formula (I-b) wherein Z is S and A is



45

50



55

j) converting the compounds of formula (I-a), as defined hereinabove under b), wherein R³ is nitro to the corresponding amino compounds by an art-known nitro to amino reduction procedure;

k) converting the compounds of formula (I-a) as defined hereinabove under b), wherein R³ is phenylmethoxy into compounds of formula (I-a) wherein R³ is hydroxy by art-known catalytic hydrogenolysis procedures;

l) converting the compounds of formula (I-a), as defined hereinabove under b), wherein R³ is amino


or hydroxy into compounds of formula (I-a) wherein R³ is (C₁₋₆alkylcarbonyl)oxy by reacting the starting compounds with an acylating agent;

5 m) converting the compounds of formula (I-a), as defined hereinabove under b), wherein R³ is an amino group into compounds of formula (I-a) wherein R³ is an azido group by converting the amino group into a diazonium group and subsequently converting the said diazonium group into an azide group;

10 or, optionally converting the compounds of formula (I) into each other following art-known group transformation procedures, and, if desired, converting the compounds of formula (I) into a therapeutically active non-toxic acid addition salt form by treatment with an appropriate acid or, conversely, converting the acid-addition salt into the free base form with alkali; and/or preparing stereoisomeric forms thereof.

Revendications

15 1. Un composé chimique ayant la formule



ou un sel par addition d'acide pharmaceutiquement acceptable de celui-ci,
25 dans laquelle


R est l'hydrogène ou un alkyle en C₁₋₆;

R¹ et R² sont chacun des membres indépendants pris dans le groupe constitué par l'hydrogène, un groupement halo, hydroxy, alkyloxy en C₁₋₆ et alkyle en C₁₋₆;

X est O ou S;

30 Alk est un alcanediyle en C₁₋₄; et


Q est un radical de formule



40 dans laquelle Y¹ et Y² sont chacun indépendamment O ou S;

R³ est un membre choisi dans le groupe consistant en l'hydrogène, un groupement halo, alkyloxy en C₁₋₆, alkyle en C₁₋₆, trifluorométhyle, nitro, cyano, hydroxy, (alkylcarbonyle en C₁₋₁₀)oxy, amino, mono- et di(alkyle en C₁₋₆)amino, (alkylcarbonyle en C₁₋₁₀)amino, phénylméthoxy et azido;

45 R⁴ est un hydrogène ou un groupement halo; ou
un radical de formule



55 dans laquelle R⁵ est l'hydrogène ou un alkyle en C₁₋₆;

Z est -S-, -CH₂- ou -CR⁶ = CR⁷-, lesdits R⁶ et R⁷ étant chacun indépendamment de l'hydrogène ou un alkyle en C₁₋₆; et

A est un radical bivalent -CH₂-CH₂-, -CH₂-CH₂-CH₂- ou -CR⁸ = CR⁹-, lesdits R⁸ et R⁹ étant chacun

indépendamment l'hydrogène, un groupement halo, amino ou alkyle en C₁-6.

2. Un composé chimique selon la revendication 1, dans lequel Q est un radical de formule (a) dans laquelle R³ est un hydrogène, un groupement halo, alkyloxy en C₁-6, alkyle en C₁-6, trifluorométhyle, hydroxy, amino ou azido et R⁴ est l'hydrogène ; ou Q est un radical de formule (b) dans laquelle R⁵ est un alkyle en C₁-6 et A est un radical bivalent -CH₂-CH₂-, -CH₂-CH₂-CH₂-ou -CR⁸ = CR⁹-, avec R⁸ et R⁹ qui sont chacun indépendamment l'hydrogène ou un alkyle en C₁-6.

3. Un composé chimique selon la revendication 2, dans lequel R est l'hydrogène, R¹ est l'hydrogène ou un groupement halo et R² est l'hydrogène, un groupement halo, hydroxy ou alkyloxy en C₁-6.

4. Un composé chimique selon la revendication 3, dans lequel Q est un radical de formule (a) dans laquelle R³ est l'hydrogène, un groupement halo ou méthyle et Y¹ est O; ou Q est un radical de formule (b) dans laquelle -Z-A- est S-CH₂-CH₂-, -S-(CH₂)₃-, -S-CR⁸ = CR⁹-, avec R⁸ et R⁹ qui sont chacun indépendamment l'hydrogène ou un groupement méthyle, -CH = CH-CR⁸ = CR⁹- avec R⁸ et R⁹ qui sont chacun indépendamment l'hydrogène ou un groupement méthyle, ou -CH₂-CH₂-CH₂-CH₂-.

5. Un composé chimique selon la revendication 4, dans lequel R¹ est l'hydrogène, et R² est l'hydrogène, un groupement halo, hydroxy ou méthoxy.

6. Un composé chimique selon la revendication 1, où le composé est la 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yle)-1-pipéridinyle]éthyle]-6,7,8,9-tétrahydro-2-méthyle-4H-pyrido[1,2-a]pyrimidine-4-one ou la 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yle)-1-pipéridinyle]éthyle]-2-méthyle-4H-pyrido[1,2-a]pyrimidine-4-one.

7. Une composition pharmaceutique comprenant un transporteur pharmaceutique convenable et en tant qu'ingrédient actif une quantité thérapeutiquement active d'un composé selon l'une quelconque des revendications 1 à 6.

8. Une composition pharmaceutique pour traiter les maladies psychotiques comprenant un transporteur pharmaceutique convenable et en tant qu'ingrédient actif une quantité active pour traiter les maladies psychotiques d'un composé selon l'une quelconque des revendications 1 à 6.

9. Une méthode pour préparer une composition pharmaceutique caractérisée en ce qu'une quantité thérapeutiquement active d'un composé selon l'une quelconque des revendications 1 à 6 est intimement mélangée avec des transporteurs pharmaceutiques convenables.

10. Un composé selon l'une quelconque des revendications 1 à 6 pour un usage en tant que médicament.


11. Un composé selon l'une quelconque des revendications 1 à 6 pour un usage en tant que médicament pour soigner les maladies psychotiques.

12. Un procédé pour préparer un composé chimique selon l'une quelconque des revendications 1 à 6, caractérisé par

45 a) mettre en réaction d'un dérivé d'ester de formule

Q-Alk-W (II)


dans laquelle W représente un résidu ester réactif avec une pipéridine de formule



55

dans un solvant inerte pour la réaction ;
b) cycliser un intermédiaire de formule


5



10

avec de l'urée ou de la thiourée, facultativement dans un solvant inerte pour la réaction, préparant ainsi un composé de formule


15



20

c) cycliser un intermédiaire de formule

25




30

dans laquelle R¹⁰ et R^{10-a} représentent chacun indépendamment un groupe partant tel que, un alkyloxy en C₁₋₆, un amino, et un mono- et di(alkyle en C₁₋₆)amino, avec une amine de formule

35

40




facultativement dans un solvant inerte pour la réaction, préparant ainsi un composé de formule (I-a) ;

d) cycliser un isocyanate ou un isothiocyanate de formule

45


50




55

avec une amine de formule (V), facultativement dans un solvant inerte pour la réaction, préparant ainsi un composé de formule (I-a) ;

e) mettre en réaction une amine de formule




avec un dérivé d'acide α -carboxylique de formule




15

dans laquelle L représente un groupe partant tel que, un groupement alkyloxy en C_{1-6} , hydroxy, halo, amino, mono- et di(alkyle en C_{1-6})amino, préparant ainsi un composé de formule




25

f) cycliser un réactif de formule



35

avec un dérivé d'acide β -aminocarboxylique de formule




45

lesdits L et L^1 représentant chacun indépendamment un groupe partant tel que, un groupement alkyloxy en C_{1-6} , hydroxy, halo, amino, mono- et di(alkyle en C_{1-6})amino, préparant ainsi un composé de formule (I-b) ;

50


g) cycliser un nitrile de formule



avec un dérivé d'acide β -aminocarboxylique de formule (IX) ledit L représentant un groupe partant tel que, un groupement alkyloxy en C_{1-6} , hydroxy, halo, amino, mono- et di(alkyle en C_{1-6})amino, préparant ainsi un composé de formule (I-b) ;
h) cycliser une 2-mercaptopyrimidone de formule

5


10



avec un réactif de formule


15

20



25

30




ou

i) cycliser une 2-mercaptopyrimidinone de formule (XI) avec un réactif de formule


35

40



préparant ainsi un composé de formule (I-b) dans laquelle Z est S et A est


45



50

lesdits composés étant représentés par la formule

55



j) convertir les composés de formule (I-a), ainsi qu'ils sont définis ci-dessus au b), dans laquelle R³ est un groupement nitro en les composés aminés correspondants par un procédé connu dans l'art de réduction de nitro en amine ;

5 k) convertir les composés de formule (I-a), ainsi qu'ils sont définis ci-dessus au b), dans laquelle R³ est un groupement phénylméthoxy en les composés de formule (I-a) dans laquelle R³ est un groupement hydroxy par des procédés connus dans l'art d'hydrogénolyse catalytique ;

10 l) convertir les composés de formule (I-a), ainsi qu'ils sont définis ci-dessus au b), dans laquelle R³ est un groupement amino ou hydroxy en les composés de formule (I-a) dans laquelle R³ est un groupement (alkylcarbonyl en C₁-₆)oxy en faisant réagir les composés de départ avec un agent d'acylation ;

15 m) convertir les composés de formule (I-a), ainsi qu'ils sont définis ci-dessus au b), dans laquelle R³ est un groupement amino en les composés de formule (I-a) dans laquelle R³ est un groupement azohydruro en convertissant le groupement amino en un groupement diazonium et en convertissant subséquemment ledit groupement diazonium en un groupement azohydruro ;

ou, convertir facultativement les composés de formule (I) chacun l'un en l'autre en suivant des procédés connus de l'art de transformation de groupes, et, si désiré, convertir les composés de formule (I) en un sel d'addition d'acide non toxique thérapeutiquement actif par traitement avec un acide approprié ou, réciproquement, convertir le sel d'addition d'acide en sa forme de base libre avec de l'alcali ; et/ou préparer des formes isomères stéréochimiques de ceux-ci.

20 **Patentansprüche**

1. Chemische Verbindung mit der Formel

25



30

oder ein pharmazeutisch annehmbares Säureadditionssalz hieron, worin

R Wasserstoff oder C₁-₆ Alkyl bedeutet;


35 R¹ und R² jeweils unabhängig voneinander Glieder aus der aus Wasserstoff, Halogen, Hydroxy, C₁-₆ Alkyloxy und C₁-₆ Alkyl bestehenden Gruppe sind;

X für O oder S steht;

Alk für C₁-₄ Alkandiyl steht; und

Q einen Rest der Formel

40



45


worin

Y¹ und Y² jeweils unabhängig voneinander für O oder S stehen;

50 R³ für ein Glied steht, ausgewählt aus der aus Wasserstoff, Halogen, C₁-₆ Alkyl, C₁-₆ Alkyloxy, Trifluormethyl, Nitro, Cyano, Hydroxy, (C₁-₁₀ Alkylcarbonyl)oxy, Amino, Mono- und Di(C₁-₆ alkyl)amino, (C₁-₁₀ Alkylcarbonyl)amino, Phenylmethoxy und Azido bestehenden Gruppe;

R⁴ für Wasserstoff oder Halogen steht; oder

55 einen Rest der Formel



bedeutet, worin

R⁵ für Wasserstoff oder C₁–₆ Alkyl steht;

10 Z die Bedeutung -S-, -CH₂- oder -CR⁶ = CR⁷- hat; wobei die Reste R⁶ und R⁷ jeweils unabhängig voneinander Wasserstoff oder C₁–₆ Alkyl bedeuten; und

A einen zweiwertigen Rest -CH₂-CH₂-, -CH₂-CH₂-CH₂- oder -CR⁸ = CR⁹- darstellt, worin R⁸ und R⁹ jeweils unabhängig voneinander Wasserstoff, Halogen, Amino oder C₁–₆ Alkyl bedeuten.

15 2. Chemische Verbindung nach Anspruch 1, worin Q einen Rest der Formel (a) bedeutet, worin R³ für Wasserstoff, Halogen, C₁–₆ Alkyl, C₁–₆ Alkyloxy, Trifluormethyl, Hydroxy, Amino oder Azido steht und R⁴ Wasserstoff bedeutet; oder Q für einen Rest der Formel (b) steht, worin R⁵ C₁–₆ Alkyl darstellt und A einen zweiwertigen Rest -CH₂-CH₂-, -CH₂-CH₂-CH₂- oder -CR⁸ = CR⁹- bedeutet, worin R⁸ und R⁹ jeweils unabhängig voneinander Wasserstoff oder C₁–₆ Alkyl bedeuten.

20 3. Chemische Verbindung nach Anspruch 2, worin R Wasserstoff darstellt, R¹ für Wasserstoff oder Halogen steht und R² Wasserstoff, Halogen, Hydroxy oder C₁–₆ Alkyloxy darstellt.

25 4. Chemische Verbindung nach Anspruch 3, worin Q einen Rest der Formel (a) bedeutet, worin R³ für Wasserstoff, Halogen oder Methyl steht und Y¹ die Bedeutung O hat; oder Q für einen Rest der Formel (b) steht, worin -Z-A- für -S-CH₂-CH₂-, -S-(CH₂)₃--, -S-CR⁸ = CR⁹- steht, worin R⁸ und R⁹ jeweils unabhängig voneinander Wasserstoff oder Methyl bedeuten, für -CH = CH-CR⁸ = CR⁹- steht, worin R⁸ und R⁹ jeweils unabhängig voneinander Wasserstoff oder Methyl bedeuten, oder für -CH₂-CH₂-CH₂-CH₂- steht.

30 5. Chemische Verbindung nach Anspruch 4, worin R¹ Wasserstoff ist und R² für Wasserstoff, Halogen, Hydroxy oder Methoxy steht.

35 6. Chemische Verbindung nach Anspruch 1, worin die Verbindung 3-[2-[4-(6-Fluor 1,2-benzisoxazol-3-yl)-1-piperidinyl] ethyl] -6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-on oder 3-[2-[4-(6-Fluor-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]2-methyl-4H-pyrido[1,2-a]pyrimidin-4-on ist.

40 7. Pharmazeutische Zusammensetzung, umfassend einen geeigneten pharmazeutischen Träger und als einen wirksamen Bestandteil eine therapeutisch wirksame Menge einer Verbindung nach einem der Ansprüche 1 bis 6.

45 8. Pharmazeutische Zusammensetzung zur Behandlung psychotischer Erkrankungen, umfassend einen geeigneten pharmazeutischen Träger und als einen wirksamen Bestandteil eine zur Behandlung psychotischer Erkrankungen wirksame Menge einer Verbindung nach einem der Ansprüche 1 bis 6.

9. Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung, dadurch gekennzeichnet, daß eine therapeutisch wirksame Menge einer Verbindung nach einem der Ansprüche 1 bis 6 innig mit geeigneten pharmazeutischen Trägern vermischt wird.

50 10. Verbindung nach einem der Ansprüche 1 bis 6 zur Verwendung als eine Medizin.


11. Verbindung nach einem der Ansprüche 1 bis 6 zur Verwendung als Medizin zur Behandlung psychotischer Erkrankungen.

55 12. Verfahren zur Herstellung einer chemischen Verbindung nach einem der Ansprüche 1 bis 6, gekennzeichnet durch:

a) Umsetzen eines Esterderivats der Formel

5
Q-Alk-W (II),

worin W einen reaktionsfähigen Esterrest bedeutet, mit einem Piperidin der Formel


10
5

10


15
in einem reaktionsinerten Lösungsmittel;

b) Cyclisieren eines Zwischenproduktes der Formel



15

20
2025
25

mit Harnstoff oder Thioharnstoff, gegebenenfalls in einem reaktionsinerten Lösungsmittel, zu einer Verbindung der Formel

30
3035
35


c) Cyclisieren eines Zwischenproduktes der Formel

40
4045
45worin R¹⁰ und R^{10-a} jeweils unabhängig voneinander eine Leaving-Gruppe, wie C₁₋₆Alkyloxy, Amino und Mono- und Di(C₁₋₆alkyl)amino bedeuten, mit einem Amin der Formel50
5055
55

gegebenenfalls in einem reaktionsinerten Lösungsmittel, unter Ausbildung einer Verbindung der Formel (I-a);

d) Cyclisieren eines Isocyanats oder Isothiocyanats der Formel

5




10

mit einem Amin der Formel (V), gegebenenfalls in einem reaktionsinerten Lösungsmittel, unter Ausbildung einer Verbindung der Formel (I-a);

e) Umsetzen eines Amins der Formel


15



20

mit einem α -Carbonylcarbonsäurederivat der Formel

25




30

worin L eine Leaving-Gruppe, wie C₁₋₆Alkyloxy, Hydroxy, Halogen, Amino, Mono- und Di(C₁₋₆alkyl)-amino bedeutet, unter Ausbildung einer Verbindung der Formel


35

40



f) Cyclisieren eines Reagens der Formel


45



50

mit einem β -Aminocarbonsäurederivat der Formel

55




10 worin L und L¹ jeweils unabhängig voneinander eine Leaving-Gruppe, wie C₁–₆Alkyloxy, Hydroxy, Halogen, Amino, Mono- und Di(C₁–₆Alkyl)amino bedeuten, unter Ausbildung einer Verbindung der Formel (I-b);

g) Cyclisieren eines Nitrils der Formel




20 mit einem β -Aminocarbonsäurederivat der Formel (IX), worin L eine Leaving-Gruppe wie C₁–₆Alkyloxy, Hydroxy, Halogen, Amino, Mono- und Di(C₁–₆alkyl)amino bedeutet, unter Ausbildung einer Verbindung der Formel (I-b);


h) Cyclisieren eines 2-Mercaptopyrimidinons der Formel



mit einem Reagens der Formel




45 unter Ausbildung einer Verbindung der Formel (I-b), worin Z für S steht, welche Verbindungen durch die Formel



55 dargestellt werden; oder


i) Cyclisieren eines 2-Mercaptopyrimidinons der Formel (XI) mit einem Reagens der Formel

5



unter Ausbildung einer Verbindung der Formel (I-b), worin Z für S steht und A die Bedeutung


10



15

hat, welche Verbindungen durch die Formel

20



25

dargestellt werden;

30

j) Überführen der Verbindungen der Formel (I-a), wie vorstehend unter b) definiert, worin R3 für Nitro steht, in die entsprechenden Aminoverbindungen nach bekannten Nitro- zu Amino-Reduktionsverfahren;
 k) Überführen der Verbindungen der Formel (I-a), wie vorstehend unter b) definiert, worin R3 für Phenylmethoxy steht, nach bekannten katalytischen Hydrogenolyseverfahren in Verbindungen der Formel (I-a), worin R3 für Hydroxy steht;

35

l) Überführen der Verbindungen der Formel (I-a), wie vorstehend unter b) definiert, worin R3 für Amino oder Hydroxy steht, durch Umsetzen der Ausgangsverbindungen mit einem Acylierungsmittel in Verbindungen der Formel (I-a), worin R3 für (C1-6 Alkylcarbonyl)oxy steht;

40

m) Überführen von Verbindungen der Formel (I-a), wie vorstehend unter b) definiert, worin R3 eine Aminogruppe bedeutet, in Verbindungen der Formel (I-a), worin R3 eine Azidogruppe darstellt, indem die Aminogruppe in eine Diazoniumgruppe umgewandelt wird und anschließend diese Diazoniumgruppe in eine Azidgruppe umgewandelt wird;

45

oder gewünschtenfalls Umwandeln der Verbindungen der Formel (I) ineinander nach bekannten Gruppentransformationsverfahren und gewünschtenfalls Überführen der Verbindungen der Formel (I) in eine therapeutisch wirksame nicht-toxische Säureadditionssalzform durch Behandeln mit einer entsprechenden Säure oder, umgekehrt, Umwandeln des Säuresadditionssalzes mit Alkali in die freie Basenform; und/oder Herstellen stereochemisch isomerer Formen hiervon.

50

55

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.
As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.